Malignant Tumors Clinical Trial
Official title:
Safety and Clinical Value of 18Fluorine-labeled BBPA PET/CT in Patients With Malignant Tumors
This study is an open-labeled phase II diagnostic clinical trial to explore the safety and clinical value of BBPA-PET/CT in suspected malignant tumor patients. The investigation regarding the clinical value of BBPA concerning the metabolic characteristics of BBPA in suspected malignant tumors. Quantitative features will be extracted to analysis the PET images. For patient who took surgery after multiple examination, histopathology, molecular pathology and LAT-1 immunohistochemistry will also be obtained.
In this study, we utilized BBPA, a novel boron amino acid, which replaces the carboxyl group of 4-boronate phenylalanine (BPA) with a boron trifluoride group (-BF3) (-COOH), as a diagnostic molecule for PET imaging of brain tumors, is also a highly efficient boron carrier for BNCT. Preclinical studies suggested [18F]BBPA to be a pan-cancer probe that transmembrane transported through large neutral amino acid transporter type-1 (LAT-1). However more studies and evidence are warranted to investigate the clinical value of BBPA PET imaging in human. This study aim to observe the safety of BBPA, and investigate the diagnostic value of BBPA in the patient with suspected malignant tumors. Patients who meet the eligibility criteria are included in clinical trials after fully communicating the condition, explaining the benefits and risks of clinical trials, clarifying the patient's willingness to include the clinical trial, and signing informed consent. The cohort number, BBPA administrative dose, imaging protocols are decided based on the investigators' preliminary data. The diagnosis and post- examination treatment are based on the recommended guideline, combined with the subject's own situation for standardized diagnosis and treatment ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02041871 -
Interest of PReOPerative Immunonutrition in Liver Surgery for Cancer
|
N/A | |
| Completed |
NCT03110783 -
Bioseal Dural Sealing Study BIOS-14-001
|
Phase 3 | |
| Recruiting |
NCT05516914 -
A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT02534506 -
Study of Urelumab in Subjects With Advanced and/or Metastatic Malignant Tumors
|
Phase 1 | |
| Recruiting |
NCT05714748 -
Application of mRNA Immunotherapy Technology in Epstein-Barr Virus-related Refractory Malignant Tumors
|
Phase 1 | |
| Not yet recruiting |
NCT01092247 -
The Effect of Ketogenic Diet on Malignant Tumors- Recurrence and Progress
|
N/A | |
| Recruiting |
NCT03160599 -
Restricted Calorie Ketogenic Diet as a Treatment in Malignant Tumors
|
N/A | |
| Recruiting |
NCT04702841 -
CAR - γ δ T Cells in the Treatment of Relapsed and Refractory CD7 Positive T Cell-derived Malignant Tumors
|
Early Phase 1 | |
| Completed |
NCT00165100 -
Dynamic Area Telethermometry (DAT) as an Imaging Modality in Patients With Cancer
|
N/A | |
| Suspended |
NCT05615974 -
A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT03542773 -
Targeted Imaging of Glutamate Carboxypeptidase II With DCFPyL-PET
|
Phase 1 | |
| Completed |
NCT05293990 -
Usefulness of Gadovist-enhanced FLAIR Imaging
|
N/A | |
| Completed |
NCT01509612 -
Additive Homeopathy in Cancer Patients
|
Phase 3 | |
| Completed |
NCT01678690 -
An Exploratory Study of Gemcitabine Hydrochloride Oral Formulation (D07001-F4) in Subjects With Malignant Tumors
|
Phase 0 | |
| Suspended |
NCT06270394 -
FAP PET/CT or PET/MR Production in the Diagnosis, Staging, and Efficacy Assessment of Malignant Tumors Application
|
N/A | |
| Completed |
NCT00412503 -
Temozolomide in Association With Topotecan in Refractory or Relapsed Malignant Tumors in Children and Adolescents
|
Phase 1 |